Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198351 · ClinicalTrials.gov registry record
An Observational Study on Teriflunomide-exposed Pregnancies
A clinical trial of Multiple Sclerosis, sponsored by Sanofi.
- Completed
- Registry status
- 220
- Enrollment target
- 2
- Study locations
NCT03198351: Completed study of Multiple Sclerosis, sponsored by Sanofi.
NCT03198351 is a study of Multiple Sclerosis that has completed, run by Sanofi. The registered enrollment target is 220 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03198351, a study of Multiple Sclerosis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies. Secondary Objective: To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pattern of minor birth defects, spontaneous abortion, stillbirth, preterm delivery, small for gestational age at birth and at 1 year follow-up.
Conditions Studied
Interventions
- DRUG Teriflunomide (HMR1726)
Study Locations (2)
California
- University of California at San Diego-Site Number:001 - San Diego
Other
- Investigational Site Number :002 - Canada
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2013-04-25 |
| Est. Completion | 2023-06-13 |
What the finished NCT03198351 record still lists
NCT03198351 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Teriflunomide (HMR1726) is the first listed.
NCT03198351 reports a single indexed study location in California, Other.
Frequently Asked Questions
What is clinical trial NCT03198351 about?
NCT03198351 is a clinical study titled "An Observational Study on Teriflunomide-exposed Pregnancies". Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies. Secondary Objective: To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pa...
What is the current status of trial NCT03198351?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2013-04-25. Estimated completion is 2023-06-13.
What conditions does trial NCT03198351 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03198351?
The interventions under investigation include: Teriflunomide (HMR1726) (DRUG).
Who is sponsoring clinical trial NCT03198351?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03198351 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03198351's enrollment target sits among peer trials
220 74th of 315 higher than 242 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI